Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The Biden administration wants to buy and send a billion free at-home COVID tests to Americans. Here's what we know so far about the contracts in terms of price, timeline and more.
-
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them. -
Former scientific head of Operation Warp Speed Moncef Slaoui explains why he is confident in existing vaccines' protection against omicron and how soon a variant-specific booster could be developed.
-
There's a new, heavily mutated COVID-19 variant called omicron. Scientists tell us what's known so far about it, what's not yet known, and what this all means for public health.
-
How much money have Pfizer and Moderna made off their COVID-19 vaccines? They're shaping up to be the most lucrative pharmaceutical products ever.
-
Pfizer says it is willing to share rights to its COVID-19 pill, Paxlovid. It's an oral antiviral drug that can be taken outside the hospital, which could be a help to low income countries.
-
Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.
-
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why. -
President Biden threw his support behind a World Trade Organization proposal that would waive intellectual property protections for COVID-19 vaccines — allowing countries to make their own vaccines.
-
Johnson & Johnson has struggled with serious supply problems. Next week, states will have 86% fewer of the doses to dole out than they did this week.
-
The COVID-19 vaccine by Johnson and Johnson has hit a snag. One the facilities making a key ingredient didn't pass quality inspection — possibly impacting 15 million doses.
-
A 1950 law allows the government to award contracts that take priority over all others for national defense. During the pandemic, the law has been used to defend the country against the coronavirus.
